All In Biotech

Drug Trial Radar · NCT04278131

BS01 in Patients With Retinitis Pigmentosa

Phase 1/2, Safety and Efficacy Trial of BS01, a Recombinant Adeno-Associated Virus Vector Expressing ChronosFP in Patients With Retinitis Pigmentosa

Last checked: Nov 19, 2026Latest source record: Jan 23, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

20

Planned (sponsor's estimate)

Start

Feb 6, 2020

Primary completion

Dec 30, 2026

Study completion Dec 30, 2029

Sponsor

Lead sponsor
Bionic Sight LLCIndustry
Sponsor type
Industry
First posted
Feb 20, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

A Phase 1/2, Safety and Efficacy Trial of BS01, a Recombinant Adeno-Associated Virus Vector Expressing ChronosFP (AAV2-CAG-ChronosFP) in Patients with Retinitis Pigmentosa

Conditions

  • Retinitis Pigmentosa

Interventions

  • BS01Drug

    Non-replicating, rep/cap-deleted, recombinant adeno-associated virus vector expressing an enhanced light-sensitive channelrhodopsin gene (ChronosFP)

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Primary Outcome MeasureTime frame: 12 months

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • New Jersey Retina

    Teaneck, New Jersey · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.